Wednesday, January 19, 2011
Diamyd Medical AB, of Stockholm, Sweden, dosed the first patient in a Phase II trial of its NP2 Enkephalin candidate aimed at reducing cancer pain. The trial will recruit about 32 subjects with severe cancer pain and will follow their pain scores and concomitant opioid pain medication usage.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.